USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: CHARLESSON, LLP
City: Oklahoma City
State: OK
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $4,005,741.00 15
SBIR Phase II $4,914,643.00 3

Award List:

Release of Angiogenic Inhibitors for Macular Edema

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yan Feng
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant) Increased vascular permeability or vascular leakage in the retina is an early and common feature of diabetic retinopathy and can result in diabetic macular edema. Vascular leakage is also responsible for cystoid macular edema (CME) secondary to cataract surgery,… More

New Thalidomide Analogs for Retinal Neovacularization

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kangmo Lu
Award Amount: $149,800.00
Abstract:
DESCRIPTION (provided by applicant): Diabetic retinopathy is a common complication of diabetes mellitus and a leading cause of blindness in the developed countries. There are two major pathological changes which impair vision in diabetic retinopathy: diabetic macular edema (DME) resulting from… More

Peptide Eyedrops for Treatment of Diabetic Retinopathy

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kangmo Lu
Award Amount: $133,750.00
Abstract:
DESCRIPTION (provided by applicant): Diabetic retinopathy is a common complication of diabetes and a leading cause of blindness in the US and the world. Diabetic macular edema (DME) and retinal neovascularization are the two major pathological alternations leading to the vision loss in diabetic… More

Treatment of Retinal Vascular Leakage Using Angiostatin

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gennadiy Moiseyev
Award Amount: $149,800.00
Abstract:
DESCRIPTION (provided by applicant): Diabetic retinopathy is a common complication of diabetes. It affects millions people and is a leading cause of blindness in the industrialized countries. In diabetic retinopathy, there are two major pathological changes responsible for vision loss, diabetic… More

Novel Linomide Analog for Treatment of Diabetic Retinopathy

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kangmo Lu
Award Amount: $248,294.00
Abstract:
DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of blindness in the world. Diabetic macular edema (DME) and retinal neovascularization (NV) are the two major pathological alternations leading to the vision loss in diabetic… More

Cocktail of Angiogenic Inhibitors for the Treatment of Diabetic Macular Edema

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gennadiy Moiseyev
Award Amount: $133,750.00
Abstract:
DESCRIPTION (provided by applicant): Vascular leakage or increased vascular permeability in the retina is a common abnormality of diabetic retinopathy and can result in diabetic macular edema (DME), a major cause of vision loss in diabetic patients. Currently, there is no effective drug therapy to… More

Novel Combretastatin A4 analogs for Treatment of Retinal Neovascularization

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Danyang Chen
Award Amount: $237,429.00
Abstract:
DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes mellitus and a leading cause of blindness in developed countries. Abnormal angiogenesis in the retina or retinal neovascularization (NV) is one of the major pathological changes in DR. Retinal NV can… More

Nanotechnology for Treatment of Diabetic Retinopathy

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kangmo Lu
Award Amount: $1,140,876.00
Abstract:
DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of blindness in the world. Diabetic macular edema (DME) and retinal neovascularization (NV) are the two major pathological alternatio ns leading to vision loss in patients with… More

A Novel Thalidomide Analog for the Treatment of Diabetic Macular Edema

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Danyang Chen
Award Amount: $840,171.00
Abstract:
DESCRIPTION (provided by applicant): Retinal vascular leakage or breakdown of the blood-retina barrier (BRB) is an early feature of diabetic retinopathy (DR) and can lead to diabetic macular edema (DME), which is the single greatest cause of vision loss in diabetic patients. Currently, there is no… More

Sustained delivery of linomide-5 for diabetic retinopathy and macular degeneratio

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $1,388,677.00
Abstract:
DESCRIPTION (provided by applicant): Linomide is a known anti-inflammatory drug. Recently we have synthesized a new analog of Linomide, linomide-5. The objective of this proposal is to develop linomide-5 as a therapeutic for treating diabetic retinopathy ( DR) and age-related macular degeneration… More

Development of a genetic CNV model for Age-Related Macular Degeneration

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $210,357.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this proposal is to develop a service for the high-throughput drug screening of compounds to treat Age-Related Macular Degeneration (AMD). In our preliminary studies, we have identified a genetically-mo dified mouse (Vldlr-/-) that presents with… More

A novel Stat3 inhibitor for treating retinal inflammation and neovascularization

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $241,279.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this proposal is to examine the efficacy of CLT-005, a novel small molecule inhibitor of Stat3, for treating inflammatory and vascular leakage of the retina of diabetic retinopathy. Retinal blood vesse l formation is known to be mediated by the… More

Novel Antioxidants for Treatment of Diabetic Retinopathy

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Danyang Chen
Award Amount: $248,094.00
Abstract:
DESCRIPTION (provided by applicant): Diabetic retinopathy is a common complication of diabetes mellitus and a leading cause of severe vision loss and blindness around the world. The current interventions for DR, laser photocoagulation and vitrectomy, imped e visual loss but do not improve vision for… More

Development of a novel anti-inflammatory treatment for clinical management of end

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Rafal A. Farjo
Award Amount: $227,286.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this proposal is to examine the efficacy of CLT-005 in reducing ocular inflammation and that occurs during endophthalmitis. Endophthalmitis occurs following the introduction of foreign pathogens into th e eye. In addition to pathogenic virulence,… More

Multitargeted Therapy for Age-related Macular Degeneration

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Danyang Chen – 405-271-2552
Award Amount: $265,992.00
Abstract:
DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is a sight-threatening disease which represents the leading cause of blindness and visual impairment in elderly individuals in developed countries. Recently, laser and photodynamic therapies with limited clinical benefit… More

Novel emulsion-based formulation of the anti-glaucoma MSH-1001 for improved topic

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ronald A. Wassel – 405-271-2552
Award Amount: $287,947.00
Abstract:
DESCRIPTION (provided by applicant): This Small Business Innovation project aims to develop an innovative eye drop formulation for the treatment of glaucoma and ocular hypertension. Charlesson has acquired from Danube Pharmaceuticals MSH-1001, a new smallmolecule compound (previously known as… More

Safety and Toxicology Studies of CLT-005 as a Therapeutic for Diabetic Macular Ed

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Rafal A. Farjo – 405-271-2557
Award Amount: $2,685,795.00
Abstract:
DESCRIPTION (provided by applicant): The objective of this proposal is to finalize development of CLT-005, a novel small molecule inhibitor of Stat3, through the performance of studies required for the submission of an investigative new drug application with the US Food and Drug Administration… More

A Small Molecule Targeting Wnt Pathway for Treatment of Diabetic Retinopathy

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Danyang Chen – 405-271-2552
Award Amount: $231,087.00
Abstract:
DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of blindness. This sight-threatening condition has become a public health challenge in the US. Currently, there is no FDA- approved drugfor DR. Laser photocoagulation has remained… More